Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
Authors:
- Georg BehrensGBGeorg Behrens
- Andre DejamADAndre Dejam
- Hartmut SchmidtHSHartmut Schmidt
- Hans-Joachim BalksHBHans-Joachim Balks
- Georg BrabantGBGeorg Brabant
- Thorsten KörnerTKThorsten Körner
- Matthias StollMSMatthias Stoll
- Reinhold E. SchmidtRSReinhold E. Schmidt
- 1 July 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (10) , F63-F70
Abstract
To evaluate metabolic abnormalities, beta-cell function, lipid profile and vascular risk factors in HIV patients on protease inhibitors (PI). Prospective cross-sectional study. Thirty-eight HIV-1-infected patients receiving at least one PI were compared with 17 PI-naive HIV patients in an oral glucose tolerance test (OGTT). Serum glucose, insulin, proinsulin, and C-peptide were determined. The fasting lipid pattern was analysed using electrophoresis and the assessment of apolipoproteins including lipoprotein (a). Fibrinogen, homocysteine, and anticardiolipin antibodies were also assessed. Twenty-seven (71%) of the PI-treated group had detectable hyperlipidaemia. Isolated hypertriglyceridaemia was present in 12 patients (44%), two (7%) of them had type V and 10 (37%) subjects had type IV hyperlipidaemia (Frederickson classification). Type IIb hyperlipidaemia defined as an increase of both very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) was found in 10 (36%) subjects, and five (18%) patients presented with isolated hypercholesterolaemia (type IIa). PI treatment was associated with significant higher fasting cholesterol, triglycerides, LDL and VLDL levels. Apolipoprotein B and E concentrations were significantly increased in patients receiving PI. Elevated concentrations of lipoprotein (a) (>30mg/dl) were detected in six (16%) of the hyperlipidaemic patients on PI. Eighteen (46%) patients on PI had impaired oral glucose tolerance and five (13%) had diabetes. Although four (24%) of the PI-naive patients were glucose intolerant, none had diabetes. Fasting concentrations and secretion response of insulin, proinsulin, and C-peptide to glucose ingestion was significantly increased in the PI-treated group suggesting a beta-cell dysfunction in addition to peripheral insulin resistance. Beta-cell abnormalities were associated with the abnormal lipid pattern and PI treatment. Combination drug regimens including PI are accompanied by impaired glucose tolerance, hyperproinsulinaemia as an indicator for beta-cell dysfunction, and lipid abnormalities proved to be significant risk factors for coronary heart disease. Moreover, PI may have an impact on the processing of proinsulin to insulin.Keywords
This publication has 25 references indexed in Scilit:
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes MellitusThe Journal of Clinical Endocrinology & Metabolism, 1998
- Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotypeMetabolism, 1995
- A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic CurvesDiabetes Care, 1994
- Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndromeThe Journal of Clinical Endocrinology & Metabolism, 1992
- Raised proinsulin concentration as early indicator of beta cell dysfunction.BMJ, 1991
- Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected menMetabolism, 1991
- Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabeticsMetabolism, 1988